VSM Wealth Advisory’s Pacific Biosciences PACB Stock Holding History

VSM Wealth Advisory’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405	Hold	241	–	–	﹤0.01%	482
2026 Q1	$318	Hold	241	–	–	﹤0.01%	481
2025 Q4	$451	Hold	241	–	–	﹤0.01%	427
2025 Q3	$308	Hold	241	–	–	﹤0.01%	423
2025 Q2	$299	Hold	241	–	–	﹤0.01%	491
2025 Q1	$284	Hold	241	–	–	﹤0.01%	480
2024 Q4	$441	Buy	+241	New	+$470	﹤0.01%	455

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VSM Wealth Advisory's PACB Position: Q2 2026 in Review

VSM Wealth Advisory held its Pacific Biosciences (PACB) position steady in Q2 2026 at 241 shares worth $405. The position accounts for ﹤0.01% of the portfolio, ranked #482.

VSM Wealth Advisory first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $451 in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

VSM Wealth Advisory held 241 shares of Pacific Biosciences worth $405 as of Q2 2026.
VSM Wealth Advisory left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of VSM Wealth Advisory's portfolio in Q2 2026, its #482 holding.
VSM Wealth Advisory first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
VSM Wealth Advisory's Pacific Biosciences position peaked at $451 in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on VSM Wealth Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.